BioCryst Pharmaceuticals, Inc.

BCRX Healthcare Drug Manufacturers Specialty & Generic

BioCryst Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $874.8 million, up 94.1% from fiscal 2024. In the quarter to June 2026, revenue grew 33.6%, EPS grew 1,450.0%, free cash flow grew 153.2% and total debt rose 15.2%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.

7.79 0.23 −2.87%
Market cap
$2.1B
P/E
0.0×
Fwd P/E
−3.5×
Dividend yield
—
F-score
7/9
Altman Z
1.83
Beneish M
−2.27
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Cash and Short Term Investments
274.95 321.06 390.79 425.78 510.95 302.59 137.78 106.01 117.68 56.20
Receivables
106.82 79.07 56.95 50.60 29.41 8.65 22.15 4.29 6.12 8.77
Inventory
5.40 8.09 28.68 27.53 15.79 7.04 1.65 1.65 0.50 0.50
Total current assets
404.35 421.97 495.97 516.50 566.14 323.80 164.35 114.35 125.39 66.99
Property, Plant, Equpment (Net)
8.78 7.78 7.91 8.62 8.71 7.11 7.35 9.14 9.55 9.92
Long-Term Investments
61.16 20.32 — 18.08 6.83 — — 22.38 41.30 8.93
Long-term assets (Other)
5.67 5.16 0.08 6.81 6.47 3.80 3.59 0.98 2.03 3.81
Total non-current assets
109.81 68.45 20.99 33.50 22.02 10.92 10.94 32.49 52.87 22.86
Total Assets
514.16 490.42 516.96 550.00 588.15 334.72 175.28 146.84 178.26 89.85
Notes Payable
— — — — — 30.00 29.56 29.12 28.68 28.24
Accounts Payable
15.83 11.64 20.89 14.36 27.81 18.71 13.99 7.77 6.34 4.27
Accrued Expenses
126.41 113.29 102.88 87.57 72.67 33.94 21.37 15.89 12.70 10.84
Current Part of Debt
52.20 32.68 23.57 2.37 1.82 31.18 9.02 4.58 6.46 28.24
Current Part of Capital Lease
1.31 1.84 1.59 0.85 1.82 1.18 1.38 0.05 0.08 —
Current Revenue (Deferred)
— — 0.00 1.22 1.42 0.15 2.12 0.22 8.48 2.02
Total current liabilities
196.07 160.38 149.99 105.51 103.72 105.65 92.34 69.48 74.84 54.36
Long Term Debt (Total)
428.67 798.05 814.11 735.06 591.42 248.32 44.70 28.08 19.50 25.48
Non-current Revenue (Deferred)
— — — — — — — 0.05 0.16 8.43
Total non-current liabilities
437.25 805.97 822.50 739.08 591.42 248.32 44.70 28.13 19.66 33.91
Total liabilities
633.31 966.35 972.49 844.60 695.14 353.98 137.03 97.61 94.49 88.27
Additional Paid In Capital
1,384.86 1,291.10 1,222.24 1,158.12 1,098.50 1,002.41 877.30 780.40 714.87 566.91
Common Stock (Net)
2.13 2.09 2.06 1.88 1.84 1.77 1.54 1.10 0.98 0.74
Retained Earnings
(1,506.18) (1,770.04) (1,681.16) (1,454.62) (1,207.50) (1,023.44) (840.63) (731.97) (631.84) (566.06)
Common Equity (Total)
(119.15) (475.93) (455.53) (294.60) (106.99) (19.26) 38.25 49.24 83.77 1.58
Shareholders Equity (Total)
(119.15) (475.93) (455.53) (294.60) (106.99) (19.26) 38.25 49.24 83.77 1.58
Shareholders Equity and Liabilities (Total)
514.16 490.42 516.96 550.00 588.15 334.72 175.28 146.84 178.26 89.85
Shares (Common)
213.06 208.54 205.77 187.91 184.35 176.88 154.08 110.06 98.41 73.78
Shareholders Equity (Tangible)
(119.15) (475.93) (455.53) (294.60) (106.99) (19.26) 38.25 49.24 83.77 1.58
Net Debt
205.92 509.66 446.88 311.64 82.29 (23.08) (84.06) (73.36) (91.72) (2.47)
Total Debt
480.87 830.72 837.68 737.43 593.24 279.50 53.72 32.66 25.97 53.72

Fold the line items

In millions of $ except per-share values · columns are period end dates